Effects of Bezafibrate on ProBNP Levels in Heart Disease Patients
Author Information
Author(s): Node Koichi, Inoue Teruo, Boyko Valentin, Goldberg Ilan, Fisman Enrique Z, Adler Yehuda, Schwammenthal Ehud, Matas Zipora, Behar Solomon, Tenenbaum Alexander
Primary Institution: Saga University Faculty of Medicine, Saga, Japan
Hypothesis
The study aimed to investigate the long-term effects of bezafibrate on ProBNP levels in patients with pre-existing coronary artery disease and advanced functional capacity impairment.
Conclusion
Long-term treatment with bezafibrate was not associated with changes in ProBNP levels in patients with coronary artery disease and advanced functional capacity impairment.
Supporting Evidence
- Bezafibrate treatment did not significantly change ProBNP levels compared to placebo.
- Patients in the bezafibrate group were older and had lower baseline ProBNP values.
- The study was part of a larger trial involving multiple hospitals.
Takeaway
The study looked at how a medicine called bezafibrate affects a heart-related marker in patients with heart problems, and it found that it didn't really change the marker over time.
Methodology
The study analyzed metabolic and inflammatory parameters from serum samples of 108 patients in a 2-year double-blind, placebo-controlled trial.
Limitations
The study included relatively few subjects and lacked data on cardiac function such as echocardiographic parameters.
Participant Demographics
Patients aged 45-74 years with a history of myocardial infarction or stable coronary artery disease.
Statistical Information
P-Value
0.3
Statistical Significance
p = 0.3
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website